longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

CMS

00867

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 15.02, within the reasonable range, cheaper than 25.31% of the time in the past 5 years, and the industry ranks 16/52, the industry Median 7.10.

15.02xP/E
HK$10.90Stock price
HK$0.73Earnings per share
15.02xP/E
Stock priceHK$10.90Earnings per shareHK$0.73

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
10.15x
Typical range
7.57x–16.78x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 7.10x
010203040

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 7.10x
0x20x40x60x80x100x
P/E ratio
Name/Symbol
01093HKCSPC PHARMA
11.72x132.34%HK$100.25B
02196HKFOSUN PHARMA
11.51x19.55%HK$44.94B
02096HKSIMCERE PHARMA
15.97x33.45%HK$28.89B
00867HKCMS
15.02x40.18%HK$26.52B
00512HKGRANDPHARMA
15.70x45.32%HK$17.41B
02005HKSSY GROUP
15.37x24.61%HK$7.80B
00460HKSIHUAN PHARM
18.63x322.92%HK$6.47B
03613HKTONGRENTANGCM
13.48x26.60%HK$4.86B
01666HKTONG REN TANG
11.51x18.02%HK$4.07B
00719HKSHANDONG XINHUA
15.25x--HK$3.78B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.